Lantern Pharma Inc. (NASDAQ: LTRN) CEO Panna Sharma and New Board Member Dr. Lee Schalop Discuss How AI Can Reshape CNS Oncology Drug Development
Lantern’s RADR(R) AI platform is helping identify optimal indications and pathways for precision cancer therapies. Dr. Schalop reflects on lessons from developing ONC201, approved for H3K27M-mutant glioma, after a 16-year journey. Both leaders highlight the potential for AI to accelerate regulatory reviews and clinical trial design. The conversation underscores how AI could reduce oncology drug timelines and costs, improving patient access to new treatments, and how STAR-001, Lantern’s new CNS cancer drug, can benefit from these AI-driven insights. In oncology, the path from molecule discovery to patient treatment often stretches over a decade and can consume hundreds of millions of…